Latest News for: dlbcl

Edit

Global CAR-T Cell Therapy Market to 2028: A Potential $15 Billion Industry with Major Focus on Diffuse Large B-Cell Lymphoma (DLBCL) Indication in 2020-2021

PR Newswire 21 Sep 2021
DUBLIN, Sept ... Majority of the companies have already started investing in them to gain a better market share in this industry.According to the analysis, the potential of the market is ~ $15 billion by 2028, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21 ... Ltd ... (US) ... 1 ... Diffuse Large B-Cell Lymphoma (DLBCL)5.3 ... U.S.6.3 ... Fax.
Edit

The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL (Form 6-K) (MorphoSys AG)

Public Technologies 27 Aug 2021
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL. - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need.
Edit

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL (MorphoSys AG)

Public Technologies 26 Aug 2021
DLBCL. - Minjuvi is a new therapeutic option for eligible DLBCL patients ... "People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis ... "DLBCL is the most common type ... Management of relapsed/refractory DLBCL.
Edit

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL

Pharmiweb 26 Aug 2021
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL. - Minjuvi is a new therapeutic option for eligible DLBCL patients ... Management of relapsed/refractory DLBCL.
Edit

Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Form 8-K) (Incyte Corporation)

Public Technologies 03 Aug 2021
) Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT) ... r/r DLBCL ... 1L DLBCL.
Edit

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Nordic Nanovector ASA)

Public Technologies 22 Jun 2021
About DLBCL DLBCL is an aggressive form of non-Hodgkin's Lymphoma (NHL) that accounts for up to 43% of all NHL cases, making it the most common form of the disease ... There are currently very few therapeutic options for patients not eligible for SCT, which makes relapsed DLBCL a serious unmet medical need.
Edit

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

PR Newswire 22 Jun 2021
NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation ... About DLBCL.
Edit

LOTIS-2 updated results demonstrate durable responses of ZYNLONTATM with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL (Form 6-K) (ADC Therapeutics SA)

Public Technologies 21 Jun 2021
LOTIS-2 updated results demonstrate durable responses of ZYNLONTATM with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL. LOTIS-3 updated Phase 1 data highlight potential of ZYNLONTA™ in combination with ibrutinib in relapsed or refractory DLBCL and MCL patients.
Edit

Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) (ADC Therapeutics SA)

Public Technologies 04 Jun 2021
Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 ... advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65.'.
Edit

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL (MorphoSys AG)

Public Technologies 04 Jun 2021
... with lenalidomide in the European Union has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.
Edit

Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL (Incyte Corporation)

Public Technologies 04 Jun 2021
... with lenalidomide in the European Union has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.
Edit

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL (Form 6-K) (MorphoSys AG)

Public Technologies 04 Jun 2021
... with lenalidomide in the European Union has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.
Edit

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Pharmiweb 04 Jun 2021
... with lenalidomide in the European Union has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.
Edit

Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials (Regeneron Pharmaceuticals Inc)

Public Technologies 17 May 2021
). May 17, 2021. Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials. Regeneron is resuming enrollment of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in its monotherapy trials of odronextamab, a CD20xCD3 bispecific antibody, following agreement with the U.S ... Contacts. ... Investor Relations.
×